WO2003026602A3 - Medicine for preventing and treating bromidrosis - Google Patents

Medicine for preventing and treating bromidrosis Download PDF

Info

Publication number
WO2003026602A3
WO2003026602A3 PCT/DE2002/003561 DE0203561W WO03026602A3 WO 2003026602 A3 WO2003026602 A3 WO 2003026602A3 DE 0203561 W DE0203561 W DE 0203561W WO 03026602 A3 WO03026602 A3 WO 03026602A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
preventing
bromidrosis
treating
treating bromidrosis
Prior art date
Application number
PCT/DE2002/003561
Other languages
German (de)
French (fr)
Other versions
WO2003026602A2 (en
Inventor
Marc Heckmann
Original Assignee
Marc Heckmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020047004120A priority Critical patent/KR100796243B1/en
Priority to MXPA04002614A priority patent/MXPA04002614A/en
Priority to US10/490,244 priority patent/US20050036966A1/en
Priority to AU2002349268A priority patent/AU2002349268B2/en
Application filed by Marc Heckmann filed Critical Marc Heckmann
Priority to HU0401913A priority patent/HU230398B1/en
Priority to JP2003530240A priority patent/JP4966478B2/en
Priority to EA200400436A priority patent/EA008146B1/en
Priority to IL16087502A priority patent/IL160875A0/en
Priority to EP15179974.9A priority patent/EP2987483B1/en
Priority to EP02781099.3A priority patent/EP1427385B1/en
Priority to UA20040402705A priority patent/UA78718C2/en
Priority to CA002461117A priority patent/CA2461117C/en
Publication of WO2003026602A2 publication Critical patent/WO2003026602A2/en
Publication of WO2003026602A3 publication Critical patent/WO2003026602A3/en
Priority to IL160875A priority patent/IL160875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the use of botulinum toxin for making a medicine for preventing and/or treating bromidrosis, and for making a cosmetic agent for attenuating body odours.
PCT/DE2002/003561 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis WO2003026602A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2003530240A JP4966478B2 (en) 2001-09-21 2002-09-23 Drugs for the prevention and treatment of odorhidrosis
US10/490,244 US20050036966A1 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis
AU2002349268A AU2002349268B2 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis
IL16087502A IL160875A0 (en) 2001-09-21 2002-09-23 The use of botulinus toxin for the manufacture of a medicament and a cosmetic
HU0401913A HU230398B1 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromhidrosis
MXPA04002614A MXPA04002614A (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis.
EA200400436A EA008146B1 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis and for attenuating body odours
KR1020047004120A KR100796243B1 (en) 2001-09-21 2002-09-23 Medicaments for prophylaxis and therapy of bromhidrosis
EP15179974.9A EP2987483B1 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromhidrosis and its cosmetic use
EP02781099.3A EP1427385B1 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis
UA20040402705A UA78718C2 (en) 2001-09-21 2002-09-23 Use of botulinum toxin for preventing and treating bromidrosis
CA002461117A CA2461117C (en) 2001-09-21 2002-09-23 Botulinus toxin for treatment of body odour
IL160875A IL160875A (en) 2001-09-21 2004-03-15 Use of botulinum toxin for the manufacture of a medicament and a cosmetic for treating body odors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10146647.1 2001-09-21
DE10146647A DE10146647A1 (en) 2001-09-21 2001-09-21 Medicines for the prophylaxis and therapy of bromhidrosis

Publications (2)

Publication Number Publication Date
WO2003026602A2 WO2003026602A2 (en) 2003-04-03
WO2003026602A3 true WO2003026602A3 (en) 2003-08-28

Family

ID=7699852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/003561 WO2003026602A2 (en) 2001-09-21 2002-09-23 Medicine for preventing and treating bromidrosis

Country Status (16)

Country Link
US (1) US20050036966A1 (en)
EP (2) EP1427385B1 (en)
JP (1) JP4966478B2 (en)
KR (1) KR100796243B1 (en)
CN (1) CN1289061C (en)
AU (1) AU2002349268B2 (en)
CA (1) CA2461117C (en)
DE (1) DE10146647A1 (en)
EA (2) EA011988B1 (en)
HU (1) HU230398B1 (en)
IL (2) IL160875A0 (en)
MX (1) MXPA04002614A (en)
PL (1) PL209639B1 (en)
UA (1) UA78718C2 (en)
WO (1) WO2003026602A2 (en)
ZA (1) ZA200402123B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943152B2 (en) 2003-03-06 2011-05-17 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7288259B2 (en) 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
BRPI0608249A2 (en) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulation, method for topical application and kit for transdermal botulinum toxin delivery
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
BRPI0914630A2 (en) * 2008-06-26 2019-09-24 Anterios Inc dermal release
US8454975B1 (en) * 2010-01-11 2013-06-04 Elizabeth VanderVeer Method for enhancing skin appearance
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19852981A1 (en) * 1998-11-17 2000-05-18 Martin Schmidt Use of botulinum toxin and its derivatives in topical treatment compositions to influence acetylcholine-dependent body functions
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19852981A1 (en) * 1998-11-17 2000-05-18 Martin Schmidt Use of botulinum toxin and its derivatives in topical treatment compositions to influence acetylcholine-dependent body functions
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943152B2 (en) 2003-03-06 2011-05-17 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
HU230398B1 (en) 2016-04-28
US20050036966A1 (en) 2005-02-17
DE10146647A1 (en) 2003-04-24
ZA200402123B (en) 2004-10-04
HUP0401913A2 (en) 2005-01-28
AU2002349268B2 (en) 2007-12-13
IL160875A0 (en) 2004-08-31
EA011988B1 (en) 2009-06-30
KR100796243B1 (en) 2008-01-21
EA200601238A1 (en) 2007-06-29
JP4966478B2 (en) 2012-07-04
WO2003026602A2 (en) 2003-04-03
CN1556693A (en) 2004-12-22
EP2987483A1 (en) 2016-02-24
JP2005507888A (en) 2005-03-24
UA78718C2 (en) 2007-04-25
EA008146B1 (en) 2007-04-27
CA2461117C (en) 2009-12-08
PL209639B1 (en) 2011-09-30
EP2987483B1 (en) 2020-12-02
EP1427385A2 (en) 2004-06-16
KR20040048895A (en) 2004-06-10
PL373528A1 (en) 2005-09-05
MXPA04002614A (en) 2005-02-17
HUP0401913A3 (en) 2008-02-28
EA200400436A1 (en) 2007-02-27
CA2461117A1 (en) 2003-04-03
EP1427385B1 (en) 2015-09-23
CN1289061C (en) 2006-12-13
IL160875A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
EP1550456A3 (en) Use of botulinum toxin in the treatment of burn pain
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA03007816A (en) Disposable underpants and method of providing the same.
EP1421948A3 (en) Use of botulinum toxins for treating sweating in humans
WO2000033863A3 (en) Therapeutic agent for the suppression of snoring noises
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
WO2002011743A3 (en) Treatment of prostate cancer
WO2003026602A3 (en) Medicine for preventing and treating bromidrosis
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
WO2002060483A3 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2002003684A3 (en) Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
AU1278600A (en) Novel therapeutic application of nicergoline
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
WO2003042240A3 (en) Polypeptides of pseudomonas aeruginosa
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
WO2002044328A3 (en) Anti-angiogenic polypeptides
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
WO2000027376A3 (en) Use of thiol compounds, oxidoreductases and/or hydrolases for the treatment of tinnitus, especially chronic tinnitus
WO2001080856A3 (en) Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 160875

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 351/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002781099

Country of ref document: EP

Ref document number: 2004/02123

Country of ref document: ZA

Ref document number: 200402123

Country of ref document: ZA

Ref document number: 2002349268

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002614

Country of ref document: MX

Ref document number: 5482

Country of ref document: GE

Ref document number: 2461117

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047004120

Country of ref document: KR

Ref document number: 1020047004119

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003530240

Country of ref document: JP

Ref document number: 20028185765

Country of ref document: CN

Ref document number: 373528

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 200400436

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020047004120

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002781099

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10490244

Country of ref document: US